FLIRT
Etude de deux stratégies d’administration du rituximab (IV et SC) en première ligne chez des patients atteints d'un Lymphome Folliculaire de faible masse tumorale (phase III)Présentations en Congrès et Publications
Publications 2023
Lysa
2023_LYSA_Randomized Phase III Trial Evaluating Sub-Cutaneous Rituximab for the First Line Treatment of Low-Tumor Burden Follicular Lymphoma: Results of a LYSA Study
J Clin Oncol . 2023 Apr 18;JCO2202327. doi: 10.1200/JCO.22.02327.
En savoir plus
Poster FLIRT | EHA 2022 |
---|---|
G. Cartron | Sub- Cutaneous Rituximab Induction Followed by Short Rituximab Maintenance Improves Progression-Free Survival in Patients with Low-Tumor Burden Follicular Lymphoma. Final Results of FLIRT Phase III Trial, a LYSA Study. |
Poster FLIRT | ASCO 2022 |
---|---|
G. Cartron | Sub- Cutaneous Rituximab Induction Followed by Short Rituximab Maintenance Improves Progression-Free Survival in Patients with Low-Tumor Burden Follicular Lymphoma. Final Results of FLIRT Phase III Trial, a LYSA Study. |
Publications 2021
Lysa
2021_LYSA_Extracellular vesicles shed by follicular lymphoma B cells promote polarization of the bone marrow stromal cell niche
Blood . 2021 Jul 8;138(1):57-70.
En savoir plus
Lysa
2021_LYSA_Follicular lymphoma triggers phenotypic and functional remodeling of the human lymphoid stromal cell landscape
Immunity . 2021 Aug 10;54(8):1901.
En savoir plus